In Vitro Activity of Avibactam (NXL104) in Combination with β-lactams Against Gram-negative Bacteria, Including OXA-48 β-lactamase-producing Klebsiella Pneumoniae
Overview
Pharmacology
Affiliations
The objective of this study was to investigate the in vitro antibacterial activity of avibactam (formerly NXL104) in combination with imipenem, cefepime or ceftazidime against Gram-negative bacteria. Bacterial isolates included: Pseudomonas aeruginosa harbouring PER-1 β-lactamase (n=14); Acinetobacter baumannii harbouring PER-1, OXA-51 and OXA-58 (n=20); carbapenem-non-susceptible Klebsiella pneumoniae (n=25) and Escherichia coli (n=1) harbouring OXA-48; carbapenem-non-susceptible E. coli (n=1) harbouring both IMP-1 metallo-β-lactamase and extended-spectrum β-lactamase (ESBL); carbapenem-non-susceptible Serratia marcescens (n=1); and carbapenem-susceptible E. coli (n=20) and K. pneumoniae isolates (n=12) with CTX-M-15 ESBL. Minimum inhibitory concentrations (MICs) of imipenem, cefepime and ceftazidime were determined in combination with 4 mg/L avibactam by the Clinical and Laboratory Standards Institute (CLSI) method on Mueller-Hinton agar. Imipenem/avibactam and ceftazidime/avibactam displayed limited potency against A. baumannii isolates, whereas cefepime/avibactam and ceftazidime/avibactam were active against P. aeruginosa. Klebsiella pneumoniae isolates with OXA-48 β-lactamase were resistant to imipenem [MIC for 90% of the organisms (MIC(90)) ≥4 mg/L]. MIC(90) values for the combination of avibactam 4 mg/L with imipenem, cefepime and ceftazidime were in the susceptible range for all strains (MIC(90)≤0.5mg/L). All E. coli and K. pneumoniae isolates with CTX-M-15 β-lactamase were inhibited at ≤1 mg/L for combinations with avibactam and 100% were susceptible by CLSI breakpoint criteria to imipenem, cefepime and ceftazidime. In conclusion, combinations of imipenem, cefepime and ceftazidime with avibactam may present a promising therapeutic strategy to treat infections due to K. pneumoniae with OXA-48 enzyme as well as K. pneumoniae and E. coli with CTX-M-15 enzyme.
Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR.
You K, Binte Mohamed Yazid N, Chong L, Hooi L, Wang P, Zhuang I NPJ Antimicrob Resist. 2025; 3(1):12.
PMID: 39984645 PMC: 11845484. DOI: 10.1038/s44259-025-00079-2.
Tian M, Yan B, Jiang R, Liu C, Li Y, Xu B BMC Microbiol. 2024; 24(1):409.
PMID: 39407114 PMC: 11481319. DOI: 10.1186/s12866-024-03571-3.
Zhang Y, Zou C, Qin J, Li M, Wang X, Wei T Can J Infect Dis Med Microbiol. 2024; 2024:5459549.
PMID: 39234528 PMC: 11374419. DOI: 10.1155/2024/5459549.
Wen L, Luo C, Chen X, Liu T, Li X, Wang M Infect Drug Resist. 2023; 16:6061-6077.
PMID: 37719649 PMC: 10503517. DOI: 10.2147/IDR.S420898.
Inhibition of β-lactamase function by de novo designed peptide.
Mishra A, Cosic I, Loncarevic I, Cosic D, Fletcher H PLoS One. 2023; 18(9):e0290845.
PMID: 37682912 PMC: 10490870. DOI: 10.1371/journal.pone.0290845.